Compare iShares MSCI China ETF (MCHI) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Teladoc Health Inc — how do they compare? iShares MSCI China ETF trades at $55.1, while Teladoc Health Inc trades at $6.62 (market cap $1.24B). The key difference: Teladoc Health Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | TDOC | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $9.72 |
52-Week Low | $50.48 | $4.47 |
Market Cap | — | $1.24B |
Enterprise Value | — | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $55.01, down 3.37% amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, with exports jumping 23% in July (CNBC, 2026-08-06). Recent institutional activity includes Empowered Funds acquiring $1.47M in shares (Defense World, 2026-08-08).
MCHI presents value opportunity trading at significant discount to US indices, with financial sector benefiting from China's yield curve. Key risks include US-China trade tensions and regulatory uncertainty. The $295B AI infrastructure plan (Bloomberg, 2026-06-09) provides long-term growth catalyst, though near-term volatility persists amid geopolitical headwinds.
Teladoc Health (TDOC) trades at $6.62, down 6.5% on the day, reflecting investor concern after a Q2 2026 revenue miss and lowered full-year guidance. The stock is technically bearish with key support at $6, while fundamentals show revenue of $2.53B in 2025 but persistent net losses, with a negative net income margin of -7.13%. Recent news highlights multiple law firm investigations into the company following its guidance cut.
The outlook remains challenging due to weak BetterHelp performance and ongoing losses, though valuation ratios like P/S of 0.49 and EV/EBITDA of 6.96 suggest potential undervaluation. Risks include competitive pressures and legal scrutiny, but analyst consensus price target of $8.88 implies upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
